WO2016164402A1 - Methods of diagnosing and treating autoimmune disease - Google Patents
Methods of diagnosing and treating autoimmune disease Download PDFInfo
- Publication number
- WO2016164402A1 WO2016164402A1 PCT/US2016/026129 US2016026129W WO2016164402A1 WO 2016164402 A1 WO2016164402 A1 WO 2016164402A1 US 2016026129 W US2016026129 W US 2016026129W WO 2016164402 A1 WO2016164402 A1 WO 2016164402A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- target
- microbe population
- sample
- purified
- target microbe
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/104—Lupus erythematosus [SLE]
Definitions
- the present disclosure is based on the discovery that certain autoimmune disease patients, such as SLE patients, display the following compared to control individuals: (1) decreases in the general microbial content in fecal samples; (2) decreases in the microbial phyla Bacteroidetes in fecal samples; (3) decreases in the Faecalibacterium genus in fecal samples; (4) decreased phylogenetic and species diversity in saliva samples; (5) increases in the microbial phyla Bacteroidetes in saliva samples; and (6) increased levels of the Prevotella genus in saliva.
- the present disclosure is therefore directed to methods of diagnosing and treating autoimmune disease patients based on abnormalities in the microbiome.
- a method for diagnosing autoimmune diseases comprises the steps of: a) obtaining a biological sample from a subject; b) isolating and purifying a target molecular population from the biological sample to yield a purified target molecular sample; c) quantifying a target microbe population in the purified target molecular sample to generate a target microbe population level; d) determining whether the target microbe population level is within an established target microbe population level range, wherein the established target microbe population level range is not associated with an autoimmune disease; and e) diagnosing the subject with the autoimmune disease if the target microbe population level is outside the established target microbe population level range, or diagnosing the subject as not having the autoimmune disease if the target microbe population level is within the established target microbe population level range.
- the method above can be used to provide a prognosis for a subject having an autoimmune disease based on the target microbe population level being within or outsi de of the established range. Even further, the method may further comprise, based on this diagnosis or prognosis, a step of administering a therapeutic composition sufficient to bring the target microbe population level within the established range that is not associated with disease.
- a method of diagnosing an autoimmune disease comprises the steps of: a) obtaining a first biological sample and a second biological sample from a subject, the first biological sample is from the oral cavity, and the second biological sample is a fecal sample; b) isolating and purifying a target molecular population from the first biological sample and the second biological sample to yield a first purified target molecular sample and a second purified target molecular sample, respectively; c) quantifying a first target microbe population in the first purified target molecular sample to generate a first target microbe population level and quantifying a second target microbe population in the second purified target molecular sample to generate a second target microbe population level; d) determining whether the first and second target microbe population levels are within a first established target microbe population level range and a second established target microbe population level range, respectively, the first and second established target microbe population level ranges are not associated with the autoimmune disease;
- a method for treating autoimmune disease comprises administering to a subject with an autoimmune disease a composition comprising microbes or spores thereof from one or both of the phyla Bacteroidetes and Firmicutes in an amount sufficient to increase the Bacteroidetes or Firmicutes microbe population to levels associated with individuals not having the autoimmune disease.
- a method for treating an autoimmune disease comprises administering to a subject with the autoimmune disease a composition comprising an anti-microbial agent in an amount sufficient to decrease the level of the phyla Bacteroidetes generally or more specifically, to the genus Prevotella in the oral cavity of the subject.
- a method for treating a subject with an autoimmune disease based on the subject's microbiome comprises the steps of: a) obtaining a biological sample from a subject; b) isolating and purifying a target molecular population from the biological sample to yield a purified target molecular sample; c) quantifying a target microbe population in the purified target molecular sample to generate a target microbe population level; d) determining whether the target microbe population level is within an established target microbe population level range, wherein the established target microbe population level range is not associated with autoimmune disease; and e) administering to the subject a therapeutic composition if the target microbe population level is outside the established target microbe population level range, wherein the therapeutic composition comprises the target microbe population if the target microbe population level is lower than the established target microbe population level range, and wherein the therapeutic composition is an anti-microbial agent specific to the target microbe population if the target microbe population level is higher than the established target
- FIG. 1A illustrates a decrease in microbial richness in the lupus fecal samples compared to the control individuals using phylogenetic and non-phylogenetic metrics as explained in Example 2.
- Fig. IB illustrates a decrease in the bacterial group Bacteroidetes in the lupus fecal samples compared to the control individuals as explained in Example 2.
- FIG. 2A illustrates decreased diversity of the lupus saliva both phylogenetically and in observed species as explained in Example 3.
- FIG. 2B illustrates higher proportions of Bacteroidetes in lupus saliva as compared to the control individuals as explained in Example 3.
- FIG. 3 illustrates highest abundance of Prevotella reported in the current data as explained in Example 3.
- the present disclosure is directed to methods of diagnosing and treating autoimmune disease patients based on abnormalities in the microbiome.
- a method for diagnosing an autoimmune disease comprises the steps of: a) obtaining a biological sample from the oral cavity of a subject; b) isolating and purifying a target molecular population from the biological sample to yield a purified target molecular sample; c) quantifying a target microbe population in the purified target molecular sample to generate a target microbe population level, wherein the target microbe population is from the phyla Bacteroidetes; d) determining whether the target microbe population level is within an established target microbe population level range, wherein the established target microbe population level range is not associated with an autoimmune disease; and e) diagnosing the subject with the autoimmune disease if the target microbe population level is outside the established target microbe population level range, or diagnosing the subject as not having the autoimmune disease if the target microbe population level is within the established target microbe population level range.
- the target microbe population is of the genus Prevotella.
- the autoimmune disease includes, but is not limited to SLE, Sjogren's Syndrome, and multiple sclerosis.
- methods for diagnosing may also be used for providing a prognosis.
- the method of the above embodiment further comprises administering a therapeutic composition to normalize the target microbe population level with the established range for not being associated with disease.
- a method of diagnosing SLE comprises the steps of: a) obtaining a first biological sample and a second biological sample from a subject, the first biological sample is from the oral cavity, and the second biological sample is a fecal sample; b) isolating and purifying a target molecular population from the first biological sample and the second biological sample to yield a first purified target molecular sample and a second purified target molecular sample, respectively; c) quantifying a first target microbe population in the first purified target molecular sample to generate a first target microbe population level and quantifying a second target microbe population in the second purified target molecular sample to generate a second target microbe population level; d) determining whether the first and second target microbe population levels are within a first established target microbe population level range and a second established target microbe population level range, respectively, the first and second established target microbe population level ranges are not associated with SLE; e) diagnosing
- a method for treating a subject with SLE based on the subject's microbiome comprises the steps of: a) obtaining a biological sample from a subject; b) isolating and purifying a target molecular population from the biological sample to yield a purified target molecular sample; c) quantifying a target microbe population in the purified target molecular sample to generate a target microbe population level; d) determining whether the target microbe population level is within an established target microbe population level range, wherein the established target microbe population level range is not associated with SLE; and e) administering to the subject a therapeutic composition if the target microbe population level is outside the established target microbe population level range, wherein the therapeutic composition comprises the target microbe population if the target microbe population level is lower than the established target microbe population level range, and wherein the therapeutic composition is an anti-microbial agent specific to the target microbe population if the target microbe population level is higher than the established target microbe population
- a method for diagnosing or determining the prognosis of an autoimmune disease comprises the steps of: a) obtaining a biological sample from a subject having the autoimmune disease or suspected of having the autoimmune disease, wherein the biological sample is of gastrointestinal origin; b) isolating and purifying a target molecular population from the biological sample to yield a purified target molecular sample; c) quantifying a target microbe population in the purified target molecular sample to generate a target microbe population level, wherein the target microbe population is from the phyla Bacteroidetes or Firmicutes or a combination of both; d) determining whether the target microbe population level is within an established target microbe population level range, wherein the established target microbe population level range is not associated with an autoimmune disease; and e) diagnosing the subject with the autoimmune disease or otherwise determining a prognosis if the target microbe population level is outside the established target microbe population level range, or diagnosing the
- the method further comprises administering to the subject a therapeutic composition sufficient to bring the target microbe population level to be within the standard range.
- the therapeutic composition comprises microbes or spores thereof from the phyla Bacteroidetes or Firmicutes or a combination of both, or more specifically, microbes or spores thereof from the genus
- the biological sample may be a fecal sample, and the target microbe population may selected from the group consisting of general microbe content, the phyla Firmicutes generally, the phyla Bacteroidetes generally, various genus of the phyla Firmicutes, including Faecalibacterium, and any combination thereof.
- the biological sample is an oral sample, and the target microbe population is selected from any of the genus in the phyla Bacteroidetes, including but not limited to Prevotella, and more generally to the overall Bacteroidetes content.
- the target molecular population is metagenomic DNA
- the purified target molecular sample is a purified metagenomic DNA sample.
- the step of quantifying the target microbe population is performed by subjecting the purified metagenomic DNA sample to metagenomic analysis, or otherwise described in the Examples herein below.
- the target molecular population is DNA
- the purified target molecular sample is a purified DNA sample.
- the step of quantifying the target microbe population is performed by subjecting the purified DNA sample to polymerase chain reaction.
- the polymerase chain reaction uses primers sufficient to amplify nucleic acid sequences specific to one or both of Bacteroidetes and Firmicutes.
- the target molecular population is metabolites and the purified target molecular sample is a purified metabolite sample.
- the step of quantifying the target microbe population is performed by subjecting the purified metabolite sample to metabolomic analysis.
- the step of quantifying the target microbe population is performed by subjecting the purified metabolite sample to mass spectrometry.
- a method for treating SLE comprises administering to a subject with SLE, a composition comprising microbes from one or both of the phyla Bacteroidetes and Firmicutes in an amount sufficient to alter the Bacteroidetes or Firmicutes microbe population to levels associated with individuals not having SLE.
- a method for treating SLE comprises administering to a subject with SLE, a composition comprising an anti-mi crobial agent in an amount sufficient to decrease the level of the phyla Bacteroidetes generally or more specifically, to the genus Prevotella in the oral cavity of the subject.
- microbe refers to one or more of the microorganisms found in the human body that are considered to be, at appropriate levels, commensal and symbiotic, and in some instances can also be pathogenic.
- target molecular population refers to the molecular entity being targeted for isolation and purification from one or more microbes in a biological sample including, but not limited to proteins, peptides, nucleic acids, chemical substances, lipids, metabolites, and other biological entities that the one or more microbes may express.
- target microbe population refers to the amount or population of the target molecular population from a particular microbe phyla, genus, or species found in a biological sample. Specific examples include microbes form the phyla Bacteroidetes or Firmicutes, or more specifically, microbes from the genus Faecalibacterium or Prevotella. This term may also refer to the general microbiome of a biological sample.
- target microbe population level refers to the amount or quantity of the target microbe population present in a given biological sample.
- the target microbe population level is a quantification of Prevotella in a given biological sample based on a DNA indication specific to Prevotella.
- an established target microbe population level range refers to a predetermined range of the target microbe population level that is found to be associated with an indication of a normal target microbe population level found in a healthy patient or otherwise not indicative as being associated with Systemic Lupus Erythematosus. This established range may not be the same across all demographics, such that a male and a female may have different established target microbe population level ranges, or such ranges may vary by age, ethnicity, and the presence of other disease states.
- the established target microbe population level range may be established by compiling a statistically compelling demographic of biological samples from individuals that do not have disease and from individuals that do have disease, and based on such, calculating a range of target microbe levels that are indicative of a disease-free state.
- the step of obtaining a biological sample can be performed directly with the subject by collecting a saliva sample, biopsy, oral swab, gingival plaque sampling, stool sampling, skin swab, and vaginal swab, or any other means known to one of skill in the art for obtaining a biological sample having a target microbe population.
- the step of obtaining the biological sample can be indirect, for example, receiving a biological sample from a separate party that is not performing the remaining steps. However, this step should not be construed to encompass any action taken by the separate party.
- the step of isolating and purifying the target molecular population from the biological sample may be performed by any method known in the art by which microbe molecules may be separated from the non-microbe components of the biological sample.
- One example of a purification and isolation method is discussed in detail below in the Examples.
- some of the therapeutic embodiments here relate to administration of anti-microbial agents specific for the microbe population targeted for decrease while other compositions may comprise the microbe desired for increase.
- anti-microbial agents sufficient to reduce the population of Bacteroidetes generally, or more specifically, the Prevotella genus in the oral cavity include erythromycin and tetracycline.
- the desired microbe or anti-microbial agent to be administered to the patient may be formulated in any manner presently established in the art sufficient for delivering microbes to humans via gavage, capsule, enema, lozenge, wafer, or fecal transplant.
- the dosing regimen may require daily or weekly administration depending on the starting level of microbe. Thus, the dosing may be required to continue throughout the life of the subject in order to maintain the appropriate level of microbe.
- the therapeutic composition may comprise microbes or spores thereof from the phyla Bacteroidetes or Firmicutes, or more specifically, microbes or spores thereof from the genus Prevotella or Faecalibacterium.
- the composition may be formulated in a number of different manners for formulating microbe-containing compositions generally known to those skilled in the art.
- the composition may be a capsule that releases its contents upon entry into an enteric environment.
- the composition may be formulated in a manner suitable for administration as an enema. Other formulations and routes of administration are contemplated and are readily appreciated by those skilled in the art.
- Fecal and saliva samples were collected from 100 patients with lupus and 100 healthy control subjects matched by gender, age, ethnicity and BMI. Fecal samples were collected using FISHERBRA D commode specimen collection systems (Therm oFisher, Waltham, MA) followed by immediate freezing of the specimens. Following return of the specimens to the researcher two 500 mg subsamples of stool were made with the remaining specimen being stored at -20°C in 30mL containers. The two 500 mg stool samples were initially broken up using bead beating with 1 mm zirconia/silica beads on a horizontal vortexer in the presence of MoBiolysis buffer.
- Each pool of metagenomic samples were then loaded onto an ILLUMINA HISEQ 2500 and sequenced using paired-end lOObp reads in the rapid read mode, with one flowcell being loaded per metagenomic pool.
- Base quality scores and raw data filters were monitored during sequencing. After sequencing the pool of reads was broken down and binned according to their respective samples via the sequence of the ligated adapter tag incorporated during the library preparation process. Tag delineation was allowed to have one mismatched base during the binning process to account for possible sequencing errors during the index read.
- Data quality for each sample was monitored using the program FastQC, identifying any sequencing artifacts, overly represented populations of low complexity reads, and overall quality across the length of each read. Any reads that did not meet the quality thresholds were either removed or trimmed back through the use of the program Trimmomatic.
- Resulting OTU tables were rarefied to a depth of 10,000 reads per sample, and alpha diversity, and taxonomic summaries were generated.
- Non-parametric Kruskal-Wallis tests were used to test for significant differences, followed by false discovery rate adjustment of p values in R. Only taxa with a median abundance of 10 counts (0.1% rel. abundance) within at least one population were filtered out. A p-value of ⁇ 0.05, and FDR of ⁇ 0.1 was used to identify taxa showing significant differences.
- Lupus Fecal Samples Microbial richness was estimated using phylogenetic (Faith's PD) and non-phylogenetic (observed species) metrics.
- Fig. 1A illustrates a statistically significant decrease in microbial richness in the lupus samples compared to control individuals. These results were consistent with the existence of a dysbiosis state in SLE.
- Fig. IB illustrates that at the phylum level, a decrease in the bacterial group Bacteroidetes was evident in the SLE samples compared to controls.
- Table 1 illustrates while both the SLE and control groups have high level of Firmicutes, they show differences when examined at the genus level.
- Faecalibacterium species was known to be associated with anti -inflammatory properties; therefore a reduction of this genus could influence SLE inflammation systemically. Low levels of Faecalibacterium prausnitzii have been associated with the autoimmune inflammatory bowel disorder, Crohn's Disease.
- Fig. 2A Microbial diversity plots from saliva for SLE and controls are shown in Fig. 2A. A trend was observed for lupus saliva to show decreased diversity both in phylogenetically, and in observed species, however, this did not attain statistical significance.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present disclosure relates to methods of diagnosing and treating Systemic Lupus Erythematosus (SLE) based on microbe population alterations in the oral cavity and intestines. It has been discovered that SLE patients present with the following abnormalities as compared to healthy individuals: (1) decreases in the general microbial diversity in fecal samples; (2) decreases in the microbial phyla Bacteroidetes in fecal samples; (3) decreases in the Faecalibacterium genus in fecal samples; (4) decreased phylogenetic and species diversity in saliva samples; (5) increases in the microbial phyla Bacteroidetes in saliva samples; and (6) increased levels of the Prevotella genus in saliva. Thus, the present disclosure provides methods of diagnosing SLE by exploiting these abnormalities. Furthermore, the present disclosure provides methods of treating SLE by resolving the above microbe abnormalities.
Description
METHODS OF DIAGNOSING AND TREATING AUTOIMMUNE DISEASE
CROSS-REFERENCE TO RELATED APPLICATIONS
[01] The present application claims priority to U.S. Provisional Application No. 62/143,571, filed April 6, 2015, the entirety of which is incorporated herein by reference.
BACKGROUND
[02] Genome wide association studies have identified hundreds of genes associated with complex, autoimmune diseases such as Systemic Lupus Erythematosus (SLE). However, the genetic architecture and aggregate risk factor explained by these studies do not completely elucidate the cause of SLE. Complex disease can be caused not only by genetic factors, but also environmental stimuli as well. While it is not feasible to research the totality of the environment with which an SLE patient interacts, one may realistically begin assaying the intimate border at which the human immune system meets the environment, and the population of organisms that can both assist and hinder humanity in its environmental interactions. This is, of course, the human microbiome.
[03] Human beings play host to a large number of microorganisms on the various surfaces of their bodies. In aggregate the total number of these organisms outstrips the human somatic and germ-line cells by at least an order of magnitude. Many of these cells, such as those living in the intestinal microbiota, exist in a symbiotic nature with their hosts, assisting with the digestion of complex plant polysaccharides as well as providing a competitively hostile environment against microorganisms that would otherwise lead to illness. Given also that humanity has evolved an exquisitely complex system of cells to prevent infection and systemic movement of microorganisms it is then of little doubt that the human immune system and the human microbiome are in constant interaction.
[04] To date, there have not been any comprehensive studies to determine if SLE patients display any irregularities in their microbiome patterns or levels. As a result, the diagnostic and therapeutic potential of the microbiome have yet to be appreciated.
SUMMARY
[05] The present disclosure is based on the discovery that certain autoimmune disease patients, such as SLE patients, display the following compared to control individuals: (1)
decreases in the general microbial content in fecal samples; (2) decreases in the microbial phyla Bacteroidetes in fecal samples; (3) decreases in the Faecalibacterium genus in fecal samples; (4) decreased phylogenetic and species diversity in saliva samples; (5) increases in the microbial phyla Bacteroidetes in saliva samples; and (6) increased levels of the Prevotella genus in saliva.
[06] The present disclosure is therefore directed to methods of diagnosing and treating autoimmune disease patients based on abnormalities in the microbiome.
[07] In an embodiment of the present invention, a method for diagnosing autoimmune diseases is provided. The method comprises the steps of: a) obtaining a biological sample from a subject; b) isolating and purifying a target molecular population from the biological sample to yield a purified target molecular sample; c) quantifying a target microbe population in the purified target molecular sample to generate a target microbe population level; d) determining whether the target microbe population level is within an established target microbe population level range, wherein the established target microbe population level range is not associated with an autoimmune disease; and e) diagnosing the subject with the autoimmune disease if the target microbe population level is outside the established target microbe population level range, or diagnosing the subject as not having the autoimmune disease if the target microbe population level is within the established target microbe population level range. Additionally, the method above can be used to provide a prognosis for a subject having an autoimmune disease based on the target microbe population level being within or outsi de of the established range. Even further, the method may further comprise, based on this diagnosis or prognosis, a step of administering a therapeutic composition sufficient to bring the target microbe population level within the established range that is not associated with disease.
[08] In another embodiment of the present invention, a method of diagnosing an autoimmune disease is provided. The method comprises the steps of: a) obtaining a first biological sample and a second biological sample from a subject, the first biological sample is from the oral cavity, and the second biological sample is a fecal sample; b) isolating and purifying a target molecular population from the first biological sample and the second biological sample to yield a first purified target molecular sample and a second purified target molecular sample, respectively; c) quantifying a first target microbe population in the first purified target molecular sample to generate a first target microbe population level and
quantifying a second target microbe population in the second purified target molecular sample to generate a second target microbe population level; d) determining whether the first and second target microbe population levels are within a first established target microbe population level range and a second established target microbe population level range, respectively, the first and second established target microbe population level ranges are not associated with the autoimmune disease; e) diagnosing the subject with the autoimmune disease, if the first and second target microbe population levels are outside the first and second established target microbe population level ranges, respectively, or diagnosing the subject as not having the autoimmune disease if the first and second target microbe population levels are within the first and second established target microbe population level ranges, respectively.
[09] In yet another embodiment of the present invention, a method for treating autoimmune disease comprises administering to a subject with an autoimmune disease a composition comprising microbes or spores thereof from one or both of the phyla Bacteroidetes and Firmicutes in an amount sufficient to increase the Bacteroidetes or Firmicutes microbe population to levels associated with individuals not having the autoimmune disease.
[10] In yet another embodiment of the present invention, a method for treating an autoimmune disease comprises administering to a subject with the autoimmune disease a composition comprising an anti-microbial agent in an amount sufficient to decrease the level of the phyla Bacteroidetes generally or more specifically, to the genus Prevotella in the oral cavity of the subject.
[11] In another embodiment, a method for treating a subject with an autoimmune disease based on the subject's microbiome is provided. The method comprises the steps of: a) obtaining a biological sample from a subject; b) isolating and purifying a target molecular population from the biological sample to yield a purified target molecular sample; c) quantifying a target microbe population in the purified target molecular sample to generate a target microbe population level; d) determining whether the target microbe population level is within an established target microbe population level range, wherein the established target microbe population level range is not associated with autoimmune disease; and e) administering to the subject a therapeutic composition if the target microbe population level is outside the established target microbe population level range, wherein the therapeutic composition comprises the target
microbe population if the target microbe population level is lower than the established target microbe population level range, and wherein the therapeutic composition is an anti-microbial agent specific to the target microbe population if the target microbe population level is higher than the established target microbe population level range.
[12] This summary is provided to introduce disclosure, certain aspects, advantages and novel features of the invention in a simplified form that are further described below in the detailed description. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter.
DRAWINGS
[13] Fig. 1A illustrates a decrease in microbial richness in the lupus fecal samples compared to the control individuals using phylogenetic and non-phylogenetic metrics as explained in Example 2.
[14] Fig. IB illustrates a decrease in the bacterial group Bacteroidetes in the lupus fecal samples compared to the control individuals as explained in Example 2.
[15] Fig. 2A illustrates decreased diversity of the lupus saliva both phylogenetically and in observed species as explained in Example 3.
[16] Fig. 2B illustrates higher proportions of Bacteroidetes in lupus saliva as compared to the control individuals as explained in Example 3.
[17] Fig. 3 illustrates highest abundance of Prevotella reported in the current data as explained in Example 3.
DESCRIPTION
[18] The present disclosure is directed to methods of diagnosing and treating autoimmune disease patients based on abnormalities in the microbiome.
[19] In an embodiment of the present invention, a method for diagnosing an autoimmune disease, comprises the steps of: a) obtaining a biological sample from the oral cavity of a subject; b) isolating and purifying a target molecular population from the biological sample to yield a purified target molecular sample; c) quantifying a target microbe population in the purified target molecular sample to generate a target microbe population level, wherein the target microbe population is from the phyla Bacteroidetes; d) determining whether the target
microbe population level is within an established target microbe population level range, wherein the established target microbe population level range is not associated with an autoimmune disease; and e) diagnosing the subject with the autoimmune disease if the target microbe population level is outside the established target microbe population level range, or diagnosing the subject as not having the autoimmune disease if the target microbe population level is within the established target microbe population level range.
[20] In one aspect of the above embodiment, the target microbe population is of the genus Prevotella. In yet another aspect of the embodiments of this disclosure, the autoimmune disease includes, but is not limited to SLE, Sjogren's Syndrome, and multiple sclerosis. In certain aspects of this disclosure, methods for diagnosing may also be used for providing a prognosis.
[21] In yet another aspect, the method of the above embodiment further comprises administering a therapeutic composition to normalize the target microbe population level with the established range for not being associated with disease.
[22] In another embodiment of the present invention, a method of diagnosing SLE is provided. The method comprises the steps of: a) obtaining a first biological sample and a second biological sample from a subject, the first biological sample is from the oral cavity, and the second biological sample is a fecal sample; b) isolating and purifying a target molecular population from the first biological sample and the second biological sample to yield a first purified target molecular sample and a second purified target molecular sample, respectively; c) quantifying a first target microbe population in the first purified target molecular sample to generate a first target microbe population level and quantifying a second target microbe population in the second purified target molecular sample to generate a second target microbe population level; d) determining whether the first and second target microbe population levels are within a first established target microbe population level range and a second established target microbe population level range, respectively, the first and second established target microbe population level ranges are not associated with SLE; e) diagnosing the subject with SLE, if the first and second target microbe population levels are outside the first and second established target microbe population level ranges, respectively, or diagnosing the subject as not
having SLE if the first and second target microbe population levels are within the first and second established target microbe population level ranges, respectively.
[23] In another embodiment, a method for treating a subject with SLE based on the subject's microbiome is provided. The method comprises the steps of: a) obtaining a biological sample from a subject; b) isolating and purifying a target molecular population from the biological sample to yield a purified target molecular sample; c) quantifying a target microbe population in the purified target molecular sample to generate a target microbe population level; d) determining whether the target microbe population level is within an established target microbe population level range, wherein the established target microbe population level range is not associated with SLE; and e) administering to the subject a therapeutic composition if the target microbe population level is outside the established target microbe population level range, wherein the therapeutic composition comprises the target microbe population if the target microbe population level is lower than the established target microbe population level range, and wherein the therapeutic composition is an anti-microbial agent specific to the target microbe population if the target microbe population level is higher than the established target microbe population level range.
[24] In an embodiment of the present invention, a method for diagnosing or determining the prognosis of an autoimmune disease, comprises the steps of: a) obtaining a biological sample from a subject having the autoimmune disease or suspected of having the autoimmune disease, wherein the biological sample is of gastrointestinal origin; b) isolating and purifying a target molecular population from the biological sample to yield a purified target molecular sample; c) quantifying a target microbe population in the purified target molecular sample to generate a target microbe population level, wherein the target microbe population is from the phyla Bacteroidetes or Firmicutes or a combination of both; d) determining whether the target microbe population level is within an established target microbe population level range, wherein the established target microbe population level range is not associated with an autoimmune disease; and e) diagnosing the subject with the autoimmune disease or otherwise determining a prognosis if the target microbe population level is outside the established target microbe population level range, or diagnosing the subject as not having the autoimmune disease or otherwise determining a prognosis if the target microbe population level is within the
established target microbe population level range. In another embodiment, the method further comprises administering to the subject a therapeutic composition sufficient to bring the target microbe population level to be within the standard range. In some embodiments, the therapeutic composition comprises microbes or spores thereof from the phyla Bacteroidetes or Firmicutes or a combination of both, or more specifically, microbes or spores thereof from the genus
Faecalibacterium.
[25] In any of the above embodiments, the biological sample may be a fecal sample, and the target microbe population may selected from the group consisting of general microbe content, the phyla Firmicutes generally, the phyla Bacteroidetes generally, various genus of the phyla Firmicutes, including Faecalibacterium, and any combination thereof. In another instance, the biological sample is an oral sample, and the target microbe population is selected from any of the genus in the phyla Bacteroidetes, including but not limited to Prevotella, and more generally to the overall Bacteroidetes content.
[26] In yet another instance, the target molecular population is metagenomic DNA, and the purified target molecular sample is a purified metagenomic DNA sample. The step of quantifying the target microbe population is performed by subjecting the purified metagenomic DNA sample to metagenomic analysis, or otherwise described in the Examples herein below. In yet another instance, the target molecular population is DNA, and the purified target molecular sample is a purified DNA sample. The step of quantifying the target microbe population is performed by subjecting the purified DNA sample to polymerase chain reaction. In certain aspects, the polymerase chain reaction uses primers sufficient to amplify nucleic acid sequences specific to one or both of Bacteroidetes and Firmicutes. In yet another instance, the target molecular population is metabolites and the purified target molecular sample is a purified metabolite sample. The step of quantifying the target microbe population is performed by subjecting the purified metabolite sample to metabolomic analysis. In another instance, the step of quantifying the target microbe population is performed by subjecting the purified metabolite sample to mass spectrometry.
[27] In yet another embodiment of the present invention, a method for treating SLE comprises administering to a subject with SLE, a composition comprising microbes from one or
both of the phyla Bacteroidetes and Firmicutes in an amount sufficient to alter the Bacteroidetes or Firmicutes microbe population to levels associated with individuals not having SLE.
[28] In yet another embodiment of the present invention, a method for treating SLE comprises administering to a subject with SLE, a composition comprising an anti-mi crobial agent in an amount sufficient to decrease the level of the phyla Bacteroidetes generally or more specifically, to the genus Prevotella in the oral cavity of the subject.
[29] As used herein, the term "microbe" refers to one or more of the microorganisms found in the human body that are considered to be, at appropriate levels, commensal and symbiotic, and in some instances can also be pathogenic.
[30] As used herein, the term "target molecular population" refers to the molecular entity being targeted for isolation and purification from one or more microbes in a biological sample including, but not limited to proteins, peptides, nucleic acids, chemical substances, lipids, metabolites, and other biological entities that the one or more microbes may express.
[31] As used herein, the term "target microbe population" refers to the amount or population of the target molecular population from a particular microbe phyla, genus, or species found in a biological sample. Specific examples include microbes form the phyla Bacteroidetes or Firmicutes, or more specifically, microbes from the genus Faecalibacterium or Prevotella. This term may also refer to the general microbiome of a biological sample.
[32] As used herein, the term "target microbe population level" refers to the amount or quantity of the target microbe population present in a given biological sample. For example, in instances where the target molecular population is DNA and the target microbe population is Prevotella, then the target microbe population level is a quantification of Prevotella in a given biological sample based on a DNA indication specific to Prevotella.
[33] As used herein, the term "an established target microbe population level range" refers to a predetermined range of the target microbe population level that is found to be associated with an indication of a normal target microbe population level found in a healthy patient or otherwise not indicative as being associated with Systemic Lupus Erythematosus. This established range may not be the same across all demographics, such that a male and a female may have different established target microbe population level ranges, or such ranges may vary by age, ethnicity, and the presence of other disease states. The established target microbe
population level range may be established by compiling a statistically compelling demographic of biological samples from individuals that do not have disease and from individuals that do have disease, and based on such, calculating a range of target microbe levels that are indicative of a disease-free state.
[34] With respect to the methods of diagnosis described herein, the step of obtaining a biological sample can be performed directly with the subject by collecting a saliva sample, biopsy, oral swab, gingival plaque sampling, stool sampling, skin swab, and vaginal swab, or any other means known to one of skill in the art for obtaining a biological sample having a target microbe population. However, the step of obtaining the biological sample can be indirect, for example, receiving a biological sample from a separate party that is not performing the remaining steps. However, this step should not be construed to encompass any action taken by the separate party.
[35] The step of isolating and purifying the target molecular population from the biological sample may be performed by any method known in the art by which microbe molecules may be separated from the non-microbe components of the biological sample. One example of a purification and isolation method is discussed in detail below in the Examples.
[36] Given that the need to raise or lower the level of a particular microbe may be different with respect to the oral cavity and the intestinal region, some of the therapeutic embodiments here relate to administration of anti-microbial agents specific for the microbe population targeted for decrease while other compositions may comprise the microbe desired for increase. Examples of anti-microbial agents sufficient to reduce the population of Bacteroidetes generally, or more specifically, the Prevotella genus in the oral cavity include erythromycin and tetracycline. With respect to the methods of treatment, the desired microbe or anti-microbial agent to be administered to the patient may be formulated in any manner presently established in the art sufficient for delivering microbes to humans via gavage, capsule, enema, lozenge, wafer, or fecal transplant. The dosing regimen may require daily or weekly administration depending on the starting level of microbe. Thus, the dosing may be required to continue throughout the life of the subject in order to maintain the appropriate level of microbe.
[37] In other embodiments, the therapeutic composition may comprise microbes or spores thereof from the phyla Bacteroidetes or Firmicutes, or more specifically, microbes or
spores thereof from the genus Prevotella or Faecalibacterium. The composition may be formulated in a number of different manners for formulating microbe-containing compositions generally known to those skilled in the art. In some instances, the composition may be a capsule that releases its contents upon entry into an enteric environment. In other instances, the composition may be formulated in a manner suitable for administration as an enema. Other formulations and routes of administration are contemplated and are readily appreciated by those skilled in the art.
[38] It is to be understood that the foregoing embodiments and aspects may be combined, as applicable, without departing from the spirit of this disclosure.
EXAMPLES
[39] The following examples are provided in order to demonstrate and further illustrate certain embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.
Materials and Methods
[40] A cohort of patients from the Oklahoma Lupus Cohort, who are actively engaged in the provision of samples, were identified. Current antibiotic use, current disease status, physical fitness, ethnicity, sex, BMI and pregnancy were assessed in this cohort to evaluate fitness for inclusion into this study. These criteria were used to ensure that the intestinal microbiota was as similar as possible, given their possibility of skewing microflora abundances.
[41] Fecal and saliva samples were collected from 100 patients with lupus and 100 healthy control subjects matched by gender, age, ethnicity and BMI. Fecal samples were collected using FISHERBRA D commode specimen collection systems (Therm oFisher, Waltham, MA) followed by immediate freezing of the specimens. Following return of the specimens to the researcher two 500 mg subsamples of stool were made with the remaining specimen being stored at -20°C in 30mL containers. The two 500 mg stool samples were initially broken up using bead beating with 1 mm zirconia/silica beads on a horizontal vortexer in the presence of MoBiolysis buffer.
[42] Saliva and possible gingival plaque sample were harvested using defined protocols already in place in our Sjogren's syndrome research clinic at OMRF. Samples were processed and stored in parallel with fecal specimens.
[43] Metagenomic DNA was isolated through the use of the MO BIO POWERSOIL DNA isolation kit (MO BIO Laboratories, Carlsbad, CA). Briefly, the lysed stool samples were incubated with a series of solutions designed to break down organic materials and remove humic acids, cellular debris, and proteins. Nucleic acids were then chromatographically purified away from any other contaminants through a series of spin columns and washes. Purified DNA was then ready for metagenomic sequencing.
[44] To identify the microorganisms present in each sample sequencing libraries compatible with the ILLUMINA SBS chemistry was generated using KAPA Library Preparation Kit (KAPA BIOSYSTEMS, Woburn, MA). Metagenomic DNA was first sheared using a COVARIS S2 sonicator, followed by an enzymatic end-repair reaction. Blunt-ended DNA molecules were then be given a single A-base tail via another enzymatic reaction and then ligated to the ILLUMINA chemistry compatible adapters. Ligated products were then enriched by a short, 8-cycle PCR amplification reaction. During the ligation reaction step, individual samples were ligated with adapters containing DNA sequences unique to their respective sample. This sample-specific barcode sequence allowed each sample, after precise quantification via fluorometry and/or qPCR, to be pooled together in sets of 10 in equimolar amounts prior to sequencing.
[45] Each pool of metagenomic samples were then loaded onto an ILLUMINA HISEQ 2500 and sequenced using paired-end lOObp reads in the rapid read mode, with one flowcell being loaded per metagenomic pool. Base quality scores and raw data filters were monitored during sequencing. After sequencing the pool of reads was broken down and binned according to their respective samples via the sequence of the ligated adapter tag incorporated during the library preparation process. Tag delineation was allowed to have one mismatched base during the binning process to account for possible sequencing errors during the index read. Data quality for each sample was monitored using the program FastQC, identifying any sequencing artifacts, overly represented populations of low complexity reads, and overall quality across the length of each read. Any reads that did not meet the quality thresholds were either removed or trimmed back through the use of the program Trimmomatic.
[46] Sequence reads for each sample were analyzed using the Ray bioinformatics suite for metagenomic studies. Ray Meta was used to generate a de novo sequence assembly of
contigs and scaffolds. This assembly was used by Ray Communities to recapitulate, via sequence homology, the overall taxonomic structure of the microbial community. Ray Ontologies also used the de novo generated contigs to deduce the overall metabolome of the microbiotic community. Through the use of the metabolomic reconstruction, it was possible to identify enriched pathways in the community. The taxonomic and metabolomic reconstructions of the intestinal and oral microflora were compared between cases and controls. Furthermore, the differences between case and control samples were checked for association with genetic data for each sample from previously completed studies containing these samples.
EXAMPLE 1
[47] In order begin characterizing the microbiome of SLE, 18 patients with SLE from the Oklahoma Lupus Cohort were enrolled; a longitudinal cohort of over 400 SLE patients were followed every 3 months at the OMRF. In parallel, a group of healthy controls were enrolled after determining the absence of autoimmune disease using a screening questionnaire. Cases and controls were matched by age, gender and ethnicity. All subjects were enrolled using consent forms approved by the OMRF institutional review board. Stool and saliva specimens were collected from each subject and processed according to established protocols for tissue preservation and banking.
[48] Following isolation of DNA from both aliquots of feces and saliva, samples were PCR amplified for 16S ribosome sequences using the Earth microbiome project protocol for 30 cycles, pooled and sequenced. Resulting reads were split by barcode, and quality filtered to remove low quality bases (q<30), and reads with ambiguous bases (TNT). Read pairs were merged to reconstruct the full ~250bp V4 ribosome fragment, and Operational taxonomic unit (OTU) clustering was performed using the Greengenes 13.8 database as reference. A clustering threshold of >97% was used to assign sequences to OTUs. Resulting OTU tables were rarefied to a depth of 10,000 reads per sample, and alpha diversity, and taxonomic summaries were generated. Non-parametric Kruskal-Wallis tests were used to test for significant differences, followed by false discovery rate adjustment of p values in R. Only taxa with a median abundance of 10 counts (0.1% rel. abundance) within at least one population were filtered out. A p-value of <0.05, and FDR of <0.1 was used to identify taxa showing significant differences.
[49] Lupus Fecal Samples. Microbial richness was estimated using phylogenetic (Faith's PD) and non-phylogenetic (observed species) metrics. Fig. 1A illustrates a statistically significant decrease in microbial richness in the lupus samples compared to control individuals. These results were consistent with the existence of a dysbiosis state in SLE.
[50] Relative abundance of microbial phyla was obtained from rarefied taxon tables. Fig. IB illustrates that at the phylum level, a decrease in the bacterial group Bacteroidetes was evident in the SLE samples compared to controls. Table 1 illustrates while both the SLE and control groups have high level of Firmicutes, they show differences when examined at the genus level. In particular, the genus Faecalibacterium demonstrated a significant reduction in SLE compared to control samples (median counts - SLE=19, control=339, FDR p-value=0.0421).
TABLE 1
Fecal Samples Median Counts
Phylum Family Genus pval FDR- Lupus Lupus Control
Adjusted
Bacteroidetes Rikenellaceae Unknown genus 0.0002 0.0171 1 131.5
Firmicutes Unknown Unknown genus 0.0003 0.0171 92.25 327.5
Clostridiales
Firmicutes Ruminococcaceae Faecalibacterium 0.0026 0.0421 19 339
Bacteroidetes Bacteroidaceae Bacteroides 0.0030 0.0421 65 746.5
Actinobacteria Coriobacteriaceae Unknown genus 0.0077 0.0886 3.5 20
Protereobacteria Alcaligenaceae Sutterella 0.0087 0.0912 1 15
Protereobacteria Desulfovibrionaceae Desulfovibrio 0.0094 0.0912 0 13
Firmicutes Christensenellaceae Unknown genus 0.0105 0.0942 2.5 18
Firmicutes Streptococcaceae Streptococcus 0.0118 0.0993 107.5 35
Actinobacteria Bifidobacteriaceae Bifidobacterium 0.0152 0.1070 356.25 67
Firmicutes Mogibacteriaceae Unknown genus 0.0153 0.1070 3.5 10
Firmicutes Lachnospiraceae Roseburia 0.0168 0.1116 4 10
Bacteroidetes Porphyromonadaceae Parabacteroides 0.0521 0.2296 2.5 31
Firmicutes Ruminococcaceae Unknown genus 0.0654 0.2296 536.5 1037
Firmicutes Lachnospiraceae Lachnospira 0.0912 0.2723 5 13
Firmicutes Ruminococcaceae Ruminococcus 0.0963 0.2723 313.75 477.5
[51] Faecalibacterium species was known to be associated with anti -inflammatory properties; therefore a reduction of this genus could influence SLE inflammation systemically. Low levels of Faecalibacterium prausnitzii have been associated with the autoimmune inflammatory bowel disorder, Crohn's Disease.
EXAMPLE 2
[52] Lupus Saliva Samples. Microbial diversity plots from saliva for SLE and controls are shown in Fig. 2A. A trend was observed for lupus saliva to show decreased diversity both in phylogenetically, and in observed species, however, this did not attain statistical significance. Fig. 2B demonstrates higher proportions of Bacteroidetes in lupus saliva, by taxanomic comparisons, compared to controls. Table 2 illustrates that, at the genus level, a predominance of the genus Prevotella in SLE saliva (median counts - SLE=2960, control=1609) was observed that is trending toward significance, however, with the current sample size the FDR corrected p- value is 0.225.
TABLE 2
Saliva Samples Median Counts
Phylum Family Genus pval FDR- Lupus Lupus Sjogren
Adjusted Control
Proteobacteria Pseudomonadaceae Pseudomonas 0.0001 0.0120 0 2 53
Firmicutes Lachnospiraceae Oribacterium 0.0020 0.0396 59 87 33.25
Fusobacteria Fusobacteriaceae Fusobacterium 0.0042 0.0539 221 505.5 661.75
Bacteroidetes Flavobacteriaceae Capnocytophaga 0.0043 0.0539 6 64 55
Proteobacteria Campylobacteriaceae Campylobacter 0.0048 0.0539 53 122 109.25
Firmicutes Gemellaceae Unknown genus 0.0050 0.0539 15 51 125.5
Firmicutes Lachnospiraceae Catonella 0.0059 0.0587 7 13 1.5
Actinobacteria Micrococcaeae Rothia 0.0067 0.0619 560 412.5 171
Spirochaetes Spirochaetaceae Treponema 0.0326 0.1798 3 18 12.25
Firmicutes Lachnospiraceae Unknown genus 0.0469 0.2243 57 44.5 14.5
Bacteroidetes Prevotellaceae Prevotella 0.0644 0.2554 2959.5 1609 1422.5
Bacteroidetes Porphyromonadaceae Porphyromonas 0.0653 0.2554 19 70 85.25
Proteobacteria Neisseriaceae Unknown genus 0.0716 0.2565 1 14 5.25
Bacteroidetes Weeksellaceae Unknown genus 0.0756 0.2567 7 12 23
Proteobacteria Pasteurellaceae Aggregatibacter 0.0846 0.2641 2 12 2
Actinobacteria Corynebacteriaceae Corynebacterium 0.0909 0.2641 6 26 25.5
Firmicutes Lachnospiraceae Moryella 0.0942 0.2641 28 20 10.75
[53] Referring to Fig. 3 and Table 3, it is observed that despite the low power of the study to detect statistically significant differences in Prevotella abundance in SLE saliva, a review of the current published literature demonstrated that of all published studies to date, that the current Lupus data demonstrates the highest abundance of Prevotella reported thus far. These results suggest that a larger study would likely define a significant difference in Prevotella in the SLE oral microbiome.
TABLE 3
Authors, Subjects Type Location Avg Seq/ 16S Seq Platform Notes Year Individual Region
I Lazarevic 753 HOME) Various 1149 V5-6 ILLUMINA
et al., 2011 USA
II Cephas et 5 Mothers USA (IL) 80,000 V4-6 ROCHE/454
al., 2011 Caregivers
II Cephas et 5 Infants USA (IL) 80,000 V4-6 ROCHE/454
al., 2011
III LMAMR 23 Healthy USA (OK) V4 ILLUMINA *35cy
III LMAMR 40 Healthy Adults USA (C&A, V4 ILLUMINA *35cy
OK)
III LMAMR 20 Adults Huanaco, V4 ILLUMINA *35cy
Peru
IV Stahringer 107 Longitudinal USA (CO) 1618 VI -2 ROCHE/454
et al., 2012 Twin Study
V Segata et 199 Adults HMP 9072 Full ROCHE/454
al., 2012
VI Pushalkar 2 Healthy Adults USA (NY) 19472 V4-5 ROCHE/454
et al., 2011
VII Nasidze et 13 Sierra Leone Sierra Leone 1370 VI -2 ROCHE/454
al., 2011
VIII Zaura et 3 Healthy Male Netherlands 10000 V5-6 ROCHE/454
al., 2009 Adults
IX Lazarevic 5 Healthy Adults Switzerland 6372 V3 ILLUMINA et al, 2010
X Crielaard et 74 Healthy Netherlands 10515 V5-6 ILLUMINA
al., 2011 Children
XI Lazarevic 1 Healthy Adult Switzerland 555152 Vl-3 ROCHE/454
et al., 2012
XI Lazarevic 1 Healthy Adult Switzerland 541687 Vl-3 ROCHE/454
et al., 2012
XII Keijser et 71 Healthy Adults Netherlands 1035 V6 ROCHE/454
al., 2008
XIII Yamanaka 19 Pre-Periodontal Japan 3356 VI -2 ROCHE/454
et al., 2012 Therapy
XIII Yamanaka 19 Post- Japan 3356 VI -2 ROCHE/454
et al., 2012 Periodontal
Therapy
XIV Said et al., 24 Healthy Adults Japan 3000 VI -2 ROCHE/454
2013
XIV Said et al., 21 Crohn's Japan 3000 VI -2 ROCHE/454
2013 Disease
XIV Said et al., 14 Ulcerative Japan 3000 VI -2 ROCHE/454
2013 Colitis
XV Yang et al., 26 Healthy China 9458 V4-5 ROCHE/454
2012
XV Yang et al., 19 Active Caries China 9458 V4-5 ROCHE/454
2012
XVI LMAMR/ 12 Sjogrens USA (OK) V4 ILLUMINA *30cy OMRF
XVI LMAMR/ 13 Lupus Control USA (OK) V4 ILLUMINA *30cy OMRF
XVI LMAMR/ 19 Lupus USA (OK) V4 ILLUMINA *30cy OMRF
[54] The foregoing description of specific embodiments of the present disclosure has been presented for purpose of illustration and description. The exemplary embodiments were chosen and described in order to best explain the principles of the invention and its practical
application, to thereby enable others skilled in the art to best utilize the invention and various embodiments with various modifications are suited to the particular use contemplated.
Claims
1. A method of diagnosing Systemic Lupus Erythematosus in a subject comprising the following steps: obtaining a biological sample from the subject; isolating and purifying a target molecular population from the biological sample to yield a purified target molecular sample; quantifying a target microbe population in the purified target molecular sample to generate a target microbe population level; determining whether the target microbe population level is within an established target microbe population level range, wherein the established target microbe population level range is not associated with Systemic Lupus Erythematosus; and diagnosing the subject with Systemic Lupus Erythematosus if the target microbe population level is outside the established target microbe population level range, or diagnosing the subject as not having Systemic Lupus Erythematosus if the target microbe population level is within the established target microbe population level range.
2. The method of claim 1, wherein the biological sample is a fecal sample and the target microbe population is Faecalibacterium.
3. The method of claim 1, wherein the target microbe population is selected from the group consisting of general microbe content, Bacteroidetes, Firmicutes, and any combination thereof.
4. The method of claim 1, wherein the biological sample is an oral sample, and the target microbe population is Prevotella.
5. The method of claim 1, wherein the target microbe population is selected from the phyla Bacteroidetes.
6. The method of any of claims 1-5, wherein the target molecular population is metagenomic DNA and the purified target molecular sample is a purified metagenomic DNA sample.
7. The method of any of claims claim 1-5, wherein the target molecular population is metagenomic DNA and the purified target molecular sample is a purified metagenomic DNA sample, and wherein the step of quantifying the target microbe population is performed by subjecting the purified metagenomic DNA sample to metagenomic analysis.
8. The method of any of claims 1-5, wherein the target molecular population is DNA and the purified target molecular sample is a purified DNA sample.
9. The method of any of claims 1-5, wherein the target molecular population is DNA and the purified target molecular sample is a purified DNA sample, and wherein the step of quantifying the target microbe population is performed by subjecting the purified DNA sample to polymerase chain reaction.
10. The method of any of claims 1-5, wherein the target molecular population is metabolites and the purified target molecular sample is a purified metabolite sample.
11. The method of any of claims 1 -5, wherein the target molecular population is metabolites and the purified target molecular sample is a purified metabolite sample, and wherein the step of quantifying the target microbe population is performed by subjecting the purified metabolite sample to metabolomic analysis.
12. The method of any of claims 1-5, wherein the target molecular population is metabolites and the purified target molecular sample is a purified metabolite sample, and wherein the step of quantifying the target microbe population is performed by subjecting the purified metabolite sample to mass spectrometry.
13. A method of diagnosing Systemic Lupus Erythematosus in a subject comprising the following steps:
obtaining a first biological sample and a second biological sample from the subject, wherein the first biological sample is from an oral cavity, and wherein the second biological sample is a fecal sample; isolating and purifying a target molecular population from the first biological sample and the second biological sample to yield a first purified target molecular sample and a second purified target molecular sample, respectively; quantifying a first target microbe population in the first purified target molecular sample to generate a first target microbe population level and quantifying a second target microbe population in the second purified target molecular sample to generate a second target microbe population level; determining whether the first and second target microbe population levels are within a first established target microbe population level range and a second established target microbe population level range, respectively, wherein the first and second established target microbe population level ranges are not associated with Systemic Lupus Erythematosus; and diagnosing the subject with Systemic Lupus Erythematosus if the first and second target microbe population levels are outside the first and second established target microbe population level ranges, respectively, or diagnosing the subject as not having Systemic Lupus
Erythematosus if the first and second target microbe population levels are within the first and second established target microbe population level ranges, respectively.
14. The method of claim 13, wherein the first target microbe population is selected from the group consisting of general microbial content, Firmicutes, and any combination thereof.
15. The method of claim 13, wherein the first target microbe population is selected from the group consisting of Bacteroidetes.
16. The method of claim 13, wherein the target molecular population is DNA and the first and second purified target molecular samples are a first purified DNA sample and a second purified DNA sample, respectively.
17. The method of claim 16, wherein the step of quantifying the first and second target microbe population is performed by subjecting the first and second purified DNA samples to polymerase chain reaction.
18. The method of claim 17, wherein the polymerase chain reaction for the first purified DNA sample uses primers sufficient to amplify nucleic acid sequences specific to one or both of Bacteroidetes and Firmicutes.
19. The method of claim 17, wherein the polymerase chain reaction for the second purified DNA sample uses primers sufficient to amplify nucleic acid sequences specific to one or both of Bacteroidetes and Firmicutes.
20. A method for treating Systemic Lupus Erythematosus comprising administering to a subject with Systemic Lupus Erythematosus a composition comprising one or both of
Bacteroidetes and Firmicutes in an amount sufficient to alter Bacteroidetes or Faecalibacterium to levels associated with individuals not having Systemic Lupus Erythematosus.
21. The method of claim 20, wherein the composition is administered as an enema.
22. A method for treating Systemic Lupus Erythematosus comprising administering to a subject with Systemic Lupus Erythematosus a composition comprising an anti-microbial agent in an amount sufficient to decrease the level of Bacteroidetes or Prevotella or both in an oral cavity of the subject.
23. The method of claim 22, wherein the composition is in the form of a lozenge.
24. The method of claim 22 or 23, wherein the composition comprises erythromycin or tetracycline.
25. A method of treating a subject with Systemic Lupus Erythematosus comprising the following steps: obtaining a biological sample from the subject;
isolating and purifying a target molecular population from the biological sample to yield a purified target molecular sample; quantifying a target microbe population in the purified target molecular sample to generate a target microbe population level; determining whether the target microbe population level is within an established target microbe population level range, wherein the established target microbe population level range is not associated with Systemic Lupus Erythematosus; and administering to the subject a therapeutic composition if the target microbe population level is outside the established target microbe population level range, wherein the therapeutic composition comprises the target microbe population if the target microbe population level is lower than the established target microbe population level range, and wherein the therapeutic composition is an anti-microbial agent specific to the target microbe population if the target microbe population level is higher than the established target microbe population level range.
26. The method of claim 25, wherein the biological sample is a fecal sample and the target microbe population is Faecalibacterium.
27. The method of claim 25, wherein the target microbe population is selected from the group consisting of general microbe content, Bacteroidetes, Firmicutes, and any combination thereof.
28. The method of claim 25, wherein the biological sample is an oral sample, and the target microbe population is Prevotella.
29. The method of claim 25 wherein the target microbe population is selected from the phyla Bacteroidetes.
30. The method of any of claims 25-29, wherein the target molecular population is metagenomic DNA and the purified target molecular sample is a purified metagenomic DNA sample.
31. The method of of any of claims 25-29, wherein the target molecular population is metagenomic DNA and the purified target molecular sample is a purified metagenomic DNA sample, and wherein the step of quantifying the target microbe population is performed by subjecting the purified metagenomic DNA sample to metagenomic analysis.
32. The method of any of claims 25-29, wherein the target molecular population is DNA and the purified target molecular sample is a purified DNA sample.
33. The method of any of claims 25-29, wherein the target molecular population is DNA and the purified target molecular sample is a purified DNA sample, and wherein the step of quantifying the target microbe population is performed by subjecting the purified DNA sample to polymerase chain reaction.
34. A method of diagnosing or providing a prognosis in a subject with an autoimmune disease comprising the following steps: obtaining a biological sample from an oral cavity of a subject; isolating and purifying a target molecular population from the biological sample to yield a purified target molecular sample; quantifying a target microbe population in the purified target molecular sample to generate a target microbe population level, wherein the target microbe population is of the genus Prevotella; determining whether the target microbe population level is within an established target microbe population level range, wherein the established target microbe population level range is not associated with the autoimmune disease; and diagnosing the subject with the autoimmune disease or otherwise providing a prognosis for the subject if the target microbe population level is outside the established target microbe population level range, or diagnosing the subject as not having the autoimmune disease or
otherwise providing a prognosis if the target microbe population level is within the established target microbe population level range.
35. The method of claim 34, further comprising the step of administering to the subject a therapeutic composition sufficient to bring the target microbe population level within the established target microbe population level range.
36. The method of any of claims 34-35, wherein the autoimmune disease is Systemic Lupus Erythematosus.
37. A method of diagnosing or providing a prognosis in a subject with an autoimmune disease comprising the following steps: obtaining a biological sample from a subject, wherein the biological sample is of gastrointestinal origin; isolating and purifying a target molecular population from the biological sample to yield a purified target molecular sample; quantifying a target microbe population in the purified target molecular sample to generate a target microbe population level, wherein the target microbe population is of the phyla
Firmicutes; determining whether the target microbe population level is within an established target microbe population level range, wherein the established target microbe population level range is not associated with the autoimmune disease; and diagnosing the subject with the autoimmune disease or otherwise providing a prognosis for the subject if the target microbe population level is outside the established target microbe population level range, or diagnosing the subject as not having the autoimmune disease or otherwise providing a prognosis if the target microbe population level is within the established target microbe population level range.
38. The method of claim 37, further comprising the step of administering to the subject a therapeutic composition sufficient to bring the target microbe population level within the established target microbe population level range.
39. The method of claim 38, wherein the therapeutic composition comprises microbes from the phyla Firmicutes or spores thereof.
40. The method of claim 38, wherein the therapeutic composition comprises microbes from the genus Faecalibacterium or spores thereof.
41. The method of claim 37, wherein the target microbe population is of the genus
Faecalibacterium.
42. The method of any of claims 37-41, wherein the autoimmune disease is Systemic Lupus Erythematosus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562143571P | 2015-04-06 | 2015-04-06 | |
US62/143,571 | 2015-04-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016164402A1 true WO2016164402A1 (en) | 2016-10-13 |
Family
ID=57072914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/026129 WO2016164402A1 (en) | 2015-04-06 | 2016-04-06 | Methods of diagnosing and treating autoimmune disease |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016164402A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110029181A (en) * | 2019-04-19 | 2019-07-19 | 中山大学附属第三医院 | A kind of the condition assessment system and its kit of systemic loupus erythematosus |
CN113832080A (en) * | 2021-11-05 | 2021-12-24 | 中山大学附属第三医院(中山大学肝脏病医院) | Marked intestinal microorganism composition for systemic lupus erythematosus diseases and application thereof |
EP3994283A4 (en) * | 2019-08-02 | 2022-10-12 | Hazan, Sabine | Method of testing for specific organisms in an individual |
US11744866B2 (en) | 2020-03-18 | 2023-09-05 | Sabine Hazan | Methods of preventing and treating COVID-19 infection with probiotics |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013053836A1 (en) * | 2011-10-11 | 2013-04-18 | Quantum Pharmaceuticals Sa | Composition comprising anaerobically cultivated human intestinal microbiota |
US20140199281A1 (en) * | 2012-11-23 | 2014-07-17 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
-
2016
- 2016-04-06 WO PCT/US2016/026129 patent/WO2016164402A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013053836A1 (en) * | 2011-10-11 | 2013-04-18 | Quantum Pharmaceuticals Sa | Composition comprising anaerobically cultivated human intestinal microbiota |
US20140199281A1 (en) * | 2012-11-23 | 2014-07-17 | Seres Health, Inc. | Synergistic bacterial compositions and methods of production and use thereof |
Non-Patent Citations (3)
Title |
---|
HEVIA ET AL.: "Intestinal dysbiosis associated with systemic lupus erythematosus", MBIO, vol. 5, no. 5, 30 September 2014 (2014-09-30), pages 1 - 10, XP055280661 * |
WYBO ET AL.: "Differentiation of cfiA-negative and cfiA-positive Bacteroides fragilis isolates by matrix-assisted laser desorption ionization-time of flight mass spectrometry", J CLIN MICROBIOL., vol. 49, no. 5, 23 February 2011 (2011-02-23), pages 1961 - 4, XP055036513 * |
ZHANG ET AL.: "Dynamics of gut microbiota in autoimmune lupus", APPL ENVIRON MICROBIOL., vol. 80, no. 24, 26 September 2014 (2014-09-26), pages 7551 - 60, XP055322704 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110029181A (en) * | 2019-04-19 | 2019-07-19 | 中山大学附属第三医院 | A kind of the condition assessment system and its kit of systemic loupus erythematosus |
EP3994283A4 (en) * | 2019-08-02 | 2022-10-12 | Hazan, Sabine | Method of testing for specific organisms in an individual |
US11744866B2 (en) | 2020-03-18 | 2023-09-05 | Sabine Hazan | Methods of preventing and treating COVID-19 infection with probiotics |
CN113832080A (en) * | 2021-11-05 | 2021-12-24 | 中山大学附属第三医院(中山大学肝脏病医院) | Marked intestinal microorganism composition for systemic lupus erythematosus diseases and application thereof |
CN113832080B (en) * | 2021-11-05 | 2023-10-20 | 中山大学附属第三医院(中山大学肝脏病医院) | Systemic lupus erythematosus disease marker intestinal microorganism combination and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Alkanani et al. | Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes | |
Zhao et al. | Alterations of the gut microbiota in Hashimoto's thyroiditis patients | |
Zhou et al. | Altered diversity and composition of gut microbiota in Chinese patients with chronic pancreatitis | |
Xun et al. | Dysbiosis and ecotypes of the salivary microbiome associated with inflammatory bowel diseases and the assistance in diagnosis of diseases using oral bacterial profiles | |
Reinold et al. | A pro-inflammatory gut microbiome characterizes SARS-CoV-2 infected patients and a reduction in the connectivity of an anti-inflammatory bacterial network associates with severe COVID-19 | |
Zhou et al. | Dynamic development of fecal microbiome during the progression of diabetes mellitus in Zucker diabetic fatty rats | |
McHardy et al. | Integrative analysis of the microbiome and metabolome of the human intestinal mucosal surface reveals exquisite inter-relationships | |
Manichanh et al. | The gut microbiota in IBD | |
Ishikawa et al. | The microbial composition of bacteroidetes species in ulcerative colitis is effectively improved by combination therapy with fecal microbiota transplantation and antibiotics | |
WO2015147432A1 (en) | Early diagnosis of metabolic and inflammatory diseases by using changes in intestinal bacterial communities and functions | |
Peña-Gonzalez et al. | Metagenomic signatures of gut infections caused by different Escherichia coli pathotypes | |
Schwensen et al. | A systematic review of studies on the faecal microbiota in anorexia nervosa: future research may need to include microbiota from the small intestine | |
Schäffler et al. | Mucosa‐attached bacterial community in Crohn's disease coheres with the clinical disease activity index | |
WO2016164402A1 (en) | Methods of diagnosing and treating autoimmune disease | |
Thuy-Boun et al. | Quantitative metaproteomics and activity-based protein profiling of patient fecal microbiome identifies host and microbial serine-type endopeptidase activity associated with ulcerative colitis | |
Nemoto et al. | Discrimination of bacterial community structures among healthy, gingivitis, and periodontitis statuses through integrated metatranscriptomic and network analyses | |
Tao et al. | Bacterial community mapping of the intestinal tract in acute pancreatitis rats based on 16S rDNA gene sequence analysis | |
Ammer-Herrmenau et al. | Comprehensive wet-bench and bioinformatics workflow for complex microbiota using Oxford Nanopore Technologies | |
Khan et al. | Analysis of the blood bacterial composition of patients with acute coronary syndrome and chronic coronary syndrome | |
Tran et al. | Associations of the Fecal Microbial Proteome Composition and Proneness to Diet-induced Obesity*[S] | |
Calderón et al. | A longitudinal study of dominant E. coli lineages and antimicrobial resistance in the gut of children living in an upper middle-income country | |
US10227651B2 (en) | Gene expression based biomarker system for irritable bowel syndrome (IBS) diagnosis | |
EP3693474A1 (en) | Methods for predicting the risk of progression and pharmacological response of a human subject suffering from multiple sclerosis | |
Stockdale et al. | Viral dark matter in the gut virome of elderly humans | |
Barraud et al. | Integrons from Aeromonas isolates collected from fish: A global indicator of antimicrobial resistance and anthropic pollution |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16777160 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16777160 Country of ref document: EP Kind code of ref document: A1 |